Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NewGenIvf Group Limited Warrants (NIVFW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: NIVFW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -46.43% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 44321 | Beta -0.3 | 52 Weeks Range 0.01 - 0.14 | Updated Date 03/15/2025 |
52 Weeks Range 0.01 - 0.14 | Updated Date 03/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -1.42% | Operating Margin (TTM) 14.69% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 558481 |
Shares Outstanding - | Shares Floating 558481 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NewGenIvf Group Limited Warrants
Company Overview
History and Background
Information on NewGenIvf Group Limited Warrants' history, founding year, milestones, and evolution is not readily available in standard financial databases. The company's warrants are relatively new to the US market. Typically, warrants are issued in conjunction with an IPO or other financing activities of the underlying stock NewGenIvf Group Limited (NIVF).
Core Business Areas
- Warrants: These represent the right to purchase shares of the underlying stock, NewGenIvf Group Limited (NIVF), at a specified price within a specific timeframe. The value of the warrants is directly tied to the performance of the underlying stock. They are essentially a derivative security linked to the equity of the company.
Leadership and Structure
Information on NewGenIvf Group Limited Warrants' leadership and organizational structure is not directly applicable since it's a derivative tied to the underlying company. Focus is on leadership of NewGenIvf Group Limited (NIVF).
Top Products and Market Share
Key Offerings
- Warrants to purchase NIVF shares: The warrants provide the holder the right, but not the obligation, to purchase NewGenIvf Group Limited (NIVF) shares at a specific exercise price before the expiration date. Market share data is not applicable to warrants, as their value is purely derived from the underlying stock. Competitors for the underlying IVF services provided by NewGenIvf Group (NIVF) include companies like Virtus Health, Monash IVF Group, and other fertility clinics.
Market Dynamics
Industry Overview
The fertility services industry is experiencing growth due to increasing infertility rates, advancements in assisted reproductive technologies (ART), and changing societal norms. Demand is driven by factors like delayed parenthood, medical conditions, and same-sex couples seeking to have children. Government regulations and ethical considerations play a significant role.
Positioning
NewGenIvf Group Limited Warrants' value is tied to the performance of NewGenIvf Group Limited (NIVF). Its positioning depends on the market perception of the underlying equity of NIVF, and the performance of the fertility market in Asia.
Total Addressable Market (TAM)
Estimates for the global fertility market vary, but projections often exceed $30 billion USD by 2027-2030. NewGenIvf's positioning within this TAM depends on its ability to capture a significant share of the market in its operating regions (predominantly Southeast Asia) and on its overall growth strategy.
Upturn SWOT Analysis
Strengths
- Potential for high leverage returns if NIVF performs well
- Lower initial investment compared to purchasing the underlying stock
- Opportunity to participate in the potential upside of NIVF's growth
Weaknesses
- Derivative instrument; highly sensitive to NIVF's stock price volatility
- Time decay: warrants lose value as expiration date approaches
- Risk of total loss if NIVF's stock price remains below the exercise price at expiration
Opportunities
- Positive developments in the fertility services industry
- Successful expansion of NIVF into new markets
- Positive news or catalysts for NIVF's stock
Threats
- Negative developments in the fertility services industry
- Decline in NIVF's financial performance
- Increased competition in the fertility market
Competitors and Market Share
Key Competitors
- The key competitors are tied to the underlying company NewGenIvf Group Limited (NIVF).
Competitive Landscape
The warrants' competitive landscape is tied to the success and competitive advantages of the underlying company, NewGenIvf Group Limited (NIVF), compared to its competitors in the fertility market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends solely on the price movement of the underlying shares of NIVF.
Future Projections: Future projections depend on the outlook for NIVF and the broader fertility services industry. Analyst estimates for NIVF would be relevant.
Recent Initiatives: Recent initiatives would pertain to activities and announcements from NewGenIvf Group Limited (NIVF).
Summary
NewGenIvf Group Limited Warrants are a derivative investment, its value being dependent on the performance of the underlying stock, NIVF. The warrants offer potential leveraged gains if NIVF stock appreciates, but involve significant risk due to time decay and the possibility of expiring worthless. Investor sentiment about the fertility market and NIVF's execution are crucial for warrant valuation. Warrant performance is inextricably linked to the underlying company's (NIVF) health and strategic direction. Potential investors should carefully consider the risks involved before investing in the warrants.
Similar Companies
Sources and Disclaimers
Data Sources:
- Financial news outlets
- Company filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investing in warrants carries significant risk, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewGenIvf Group Limited Warrants
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-04-04 | Co-Founder, Chairman & CEO Mr. Wing Fung Siu | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 70 | Website https://newgenivf.com |
Full time employees 70 | Website https://newgenivf.com | ||
NewGenIvf Group Limited provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, and Kyrgyzstan. Its services includes mitochondrial replacement (MRT) therapy in reproductive, intrauterine insemination, mrt techniques, in-vitro fertilization /ICSI, hysteroscopy, semen analysis, TESE/TESA/PESA, embryo transfer, egg freezing, and chromosome screening, as well as surrogacy and ancillary caring services. The company was founded in 2010 and is based in Central, Hong Kong.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.